Dr William Parker

MA, MB, BChir, MRCS, MRCP

Department of Infection, Immunity and Cardiovascular Disease

Clinical Research Fellow (Staff Candidate PhD)

w.parker@sheffield.ac.uk
+44 114 226 6159

+44 114 305 2003 (fax)

The Cardiovascular Research Unit (CVRU), Sam Fox House, Northern General Hospital

Full contact details

Dr William Parker
Department of Infection, Immunity and Cardiovascular Disease
The Cardiovascular Research Unit (CVRU), Sam Fox House
Northern General Hospital
Herries Road
Sheffield
S5 7AU

Profile

I studied Medicine and Pharmacology at the University of Cambridge before returning to my home city of Sheffield to complete the Academic Foundation and Core Medical Training Programmes.

I obtained Membership of the Royal College of Surgeons of England in 2013 and of the Royal Colleges of Physicians of the United Kingdom in 2014.

In 2015, I was appointed Clinical Research Fellow in Cardiology at the University of Sheffield with clinical tenure at the South Yorkshire Cardiothoracic Centre, Northern General Hospital.

In 2018, I was awarded a three-year British Heart Foundation Clinical Training Fellowship and am currently studying for a PhD under the primary supervision of Professor Rob Storey.

Research interests

My main research interest is in improving the quality and safety of anti-thrombotic therapy for ischaemic heart disease.

Specifically, I am currently investigating the dose-dependent effects of aspirin when used in combination with other antithrombotic agents and how drug regimens can be optimised to augment benefits whilst reducing harm.

I have a general interest in the pharmacological management of cardiovascular disease and how this can be improved and investigated.

I also study and research the history of medicine and am in the process of completing the Diploma in the History of Medicine at the Society of Apothecaries of London.

Current Projects:

The WILLOW programme (a series of randomised controlled trials investigating the dose-dependent effects of aspirin in combination with other antithrombotic drugs).
Co-investigator on a wide range of local and multi-centre clinical trials within the Cardiovascular Research Unit.

Publications

Journal articles

Parker WAE & Storey RF (2019) Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal, 40(24), 1971-1974.
Parker WAE, Orme RC, Hanson J, Stokes HM, Bridge CM, Shaw PA, Sumaya W, Thorneycroft K, Petrucci G, Porro B , Judge HM et al (2019) Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 30(2), 148-157. View this article in WRRO
Parker WAE, Eriksson N, Becker RC, Voora D, Åkerblom A, Himmelmann A, James SK, Wallentin L & Storey RF (2019) Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 30(5), 579-588.
Orme RC, Parker WAE, Thomas MR, Judge HM, Baster K, Sumaya W, Morgan KP, McMellon HC, Richardson JD, Grech ED , Wheeldon NM et al (2018) Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
Sumaya W, Parker W, Fretwell R, Hall I, Barmby D, Richardson J, Iqbal J, Adam Z, Morgan K, Gunn J , Mason A et al (2018) Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thrombosis and Haemostasis, 118(07), 1250-1256. View this article in WRRO
Parker WA, Bhatt DL, Prats J, Day JRS, Steg PG, Stone GW, Hamm CW, Mahaffey KW, Price MJ, Michael Gibson C , White HD et al (2017) Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 117(06), 1093-1100.
Parker WAE & Storey RF (2016) Ticagrelor: agonising over its mechanisms of action. Blood, 128(23), 2595-2597.
Storey RF & Parker WAE (2016) Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 134(11), 793-796. View this article in WRRO
Parker WAE & Storey RF (2016) Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart, 102(10), 783-789.
Maguire JJ, Parker WAE, Foord SM, Bonner TI, Neubig RR & Davenport AP (2009) International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature. Pharmacological Reviews, 61(1), 1-8.
Parker WAE & Storey RF () Choosing a perspective on mortality with DAPT. European Heart Journal, ehv610-ehv610.

Chapters

Parker W & Storey R (2018) Acute coronary syndromes: Thrombotic Response

Teaching interests

I contribute to the teaching of medical students at various stages of the MB ChB course, as well as lecturing on the Masters in Cardiovascular Research and Masters in Genomic Medicine programmes.

I am studying for a Postgraduate Certificate in Teaching and Learning for Higher Education with the School of Education at the University of Sheffield.

I am also passionate about public engagement and have recently devised and delivered sessions for the NHS 70th Anniversary celebrations, Sheffield Ignite Academy, Pecha Kucha foundation and the Millennium Galleries, Sheffield (Leonardo Da Vinci exhibition).

Professional activities: I was elected as a Nucleolus member of the European Society of Cardiology Working Group on Thrombosis Young Researchers in October 2018.